Ratiopharm under bribery investigation

30 April 2006

German pharmaceutical firm Ratiopharm is being inves-tigated on suspicion of having defrauded the health insur-ance system by "bribing" doctors to prescribe its generic versions of branded drugs. The General Public Prosecutor's office in the Bavarian city of Stuttgart has launched an official investigation into the company following media reports and individual complaints.

Ratiopharm is accused of bribing doctors with cash and expensive electronic devices to prescribe its medications to patients - even if they cost more than those on offer by competitors.

Public Prosecutor Rainer Christ said his office had reason to believe the company could have systematically deceived Germany's health insurance system. He said: "we are of the opinion that grounds for suspicion of fraud and betrayal exist and that investigations are necessary."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight